Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News SAGE Therapeutics Inc SAGE

Healthcare Biotechnology
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of... see more

Recent & Breaking News (NDAQ:SAGE)

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire August 5, 2023

Sage Therapeutics to Host Business Update Webcast and Announce Second Quarter Financial Results on Monday, August 7, 2023

Business Wire August 4, 2023

FDA Approves ZURZUVAE(TM) (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

Business Wire August 4, 2023

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire August 4, 2023

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile July 28, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire July 28, 2023

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile July 27, 2023

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Accesswire July 27, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile July 26, 2023

Sage Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

Business Wire June 5, 2023

Sage Therapeutics to Present at Upcoming May Investor Conferences

Business Wire May 3, 2023

Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress

Business Wire May 2, 2023

Sage Therapeutics to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023

Business Wire April 18, 2023

Sage Therapeutics to Present at the Stifel 2023 CNS Days

Business Wire March 22, 2023

Sage Therapeutics Appoints Jessica Federer to Board of Directors

Business Wire March 16, 2023

Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone

Business Wire March 8, 2023

Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

Business Wire February 28, 2023

Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington's Disease

Business Wire February 22, 2023

Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress

Business Wire February 16, 2023

Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

GlobeNewswire February 6, 2023